Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Kevin Buehler, a director at Precision Biosciences Inc. (NASDAQ:DTIL), recently purchased 4,523 shares of the company’s common stock. The shares were acquired on March 26, 2025, at a weighted average price of $4.67 per share, resulting in a total transaction value of $21,122. Following this purchase, Buehler holds a total of 13,235 shares in the company. The purchase comes as the stock trades significantly below its 52-week high of $15.97, with InvestingPro analysis indicating the stock is currently undervalued.
The shares were bought in multiple transactions, with prices ranging from $4.62 to $4.67, as noted in the filing. The stock has experienced significant pressure, dropping 16.7% in the past week alone. InvestingPro subscribers can access detailed insider trading patterns and 8 additional key insights about DTIL’s financial health and market position.
In other recent news, Precision BioSciences has made significant strides in its gene editing programs. The company has received FDA clearance to expand its Phase 1 ELIMINATE-B study for PBGENE-HBV, a gene editing therapy for chronic hepatitis B, into the United States. This expansion is part of a broader strategy, with the trial already active in Moldova, Hong Kong, and New Zealand. Additionally, Precision BioSciences announced promising preclinical data for PBGENE-DMD, a therapeutic candidate for Duchenne muscular dystrophy, which has led H.C. Wainwright to reaffirm its Buy rating and a $60 price target for the company. The firm is optimistic about the potential of Precision’s ARCUS platform in developing effective treatments.
In another development, Precision BioSciences’ partner iECURE reported a complete clinical response in a Phase 1/2 trial for Ornithine Transcarbamylase deficiency using the ARCUS platform. This success prompted BMO Capital to upgrade Precision BioSciences from Market Perform to Outperform, with a $34 price target. The company also announced the retirement of Dr. Sam Wadsworth from its Board of Directors, with no immediate impact on its strategic direction. Precision BioSciences continues to focus on addressing diseases with high unmet needs, leveraging its ARCUS genome editing platform for potentially transformative therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.